300 results on '"Rankin, N"'
Search Results
2. From ideal to actual practice: Tailoring a clinical pathway to address anxiety or depression in patients with cancer and planning its implementation across individual clinical services
- Author
-
Butow, P. N., Shepherd, H. L., Cuddy, J., Harris, M., He, S., Masya, L., Rankin, N. M., Grimison, P., Girgis, A., and Shaw, J. M.
- Published
- 2021
- Full Text
- View/download PDF
3. MetaNetter 2: A Cytoscape plugin for ab initio network analysis and metabolite feature classification
- Author
-
Burgess, K.E.V., Borutzki, Y., Rankin, N., Daly, R., and Jourdan, F.
- Published
- 2017
- Full Text
- View/download PDF
4. What Strategies Are Recommended for Potential Implementation of a National Lung Cancer Screening in Australia?
- Author
-
Rankin, N., primary, Dodd, R.H., additional, Dunlop, K.L.A., additional, Stone, E., additional, Yap, M.L., additional, Rhee, J., additional, Sharman, A.R., additional, McCullough, S., additional, and Marshall, H.M., additional
- Published
- 2023
- Full Text
- View/download PDF
5. Effect of core versus enhanced implementation strategies on adherence to a clinical pathway for managing anxiety and depression in cancer patients in routine care: a cluster randomised controlled trial.
- Author
-
Butow, P, Faris, MM, Shaw, J, Kelly, P, He, S, Harris, M, Cuddy, J, Masya, L, Geerligs, L, Kelly, B, Girgis, A, Rankin, N, Beale, P, Hack, TF, Kirsten, L, Dhillon, H, Grimison, P, Viney, R, Clayton, JM, Schlub, T, ADAPT Program Group, Shepherd, HL, Butow, P, Faris, MM, Shaw, J, Kelly, P, He, S, Harris, M, Cuddy, J, Masya, L, Geerligs, L, Kelly, B, Girgis, A, Rankin, N, Beale, P, Hack, TF, Kirsten, L, Dhillon, H, Grimison, P, Viney, R, Clayton, JM, Schlub, T, ADAPT Program Group, and Shepherd, HL
- Abstract
BACKGROUND: Optimal strategies to facilitate implementation of evidence-based clinical pathways are unclear. We evaluated two implementation strategies (Core versus Enhanced) to facilitate implementation of a clinical pathway for the management of anxiety and depression in cancer patients (the ADAPT CP). METHODS: Twelve cancer services in NSW Australia were cluster randomised, stratified by service size, to the Core versus Enhanced implementation strategy. Each strategy was in place for 12 months, facilitating uptake of the ADAPT CP (the intervention being implemented). The Core strategy included a lead team with champions, staff training and awareness campaigns prior to implementation, plus access to feedback reports and telephone or online support during implementation. The Enhanced strategy included all Core supports plus monthly lead team meetings, and proactive, ongoing advice on managing barriers, staff training and awareness campaigns throughout implementation. All patients at participating sites were offered the ADAPT CP as part of routine care, and if agreeable, completed screening measures. They were allocated a severity step for anxiety/depression from one (minimal) to five (severe) and recommended management appropriate to their severity step. Multi-level mixed-effect regression analyses examined the effect of Core versus Enhanced implementation strategy on adherence to the ADAPT CP (binary primary outcome: adherent ≥ 70% of key ADAPT CP components achieved versus non-adherent < 70%), with continuous adherence as a secondary outcome. Interaction between study arm and anxiety/depression severity step was also explored. RESULTS: Of 1280 registered patients, 696 (54%) completed at least one screening. As patients were encouraged to re-screen, there were in total 1323 screening events (883 in Core and 440 in Enhanced services). The main effect of implementation strategy on adherence was non-significant in both binary and continuous analyses. Anxiety/depressi
- Published
- 2023
6. Harnessing Evidence in the Policy Process
- Author
-
White, Kathleen M., primary and Rankin, N. Audra, additional
- Published
- 2018
- Full Text
- View/download PDF
7. EP10.01-005 Australian Lung Cancer Survivors Experiences of Novel Treatments, Healthcare, and Ongoing Physical and Psychological Needs
- Author
-
Laidsaar-Powell, R., primary, Butow, P., additional, Brown, B., additional, Mander, K., additional, Young, J., additional, Stone, E., additional, Chin, V., additional, Banks, E., additional, Lim, C., additional, and Rankin, N., additional
- Published
- 2022
- Full Text
- View/download PDF
8. EP04.01-025 Implementation of Electronic Patient Reported Outcomes in Routine Cancer Care
- Author
-
Girgis, A., primary, Bamgboje-Ayodele, A., additional, Rincones, O., additional, Vinod, S., additional, Avery, S., additional, Descallar, J., additional, Arnold, B., additional, Arnold, A., additional, Bray, V., additional, Durcinoska, I., additional, Rankin, N., additional, and Delaney, G., additional
- Published
- 2022
- Full Text
- View/download PDF
9. EP04.01-023 Development of an Australia and New Zealand Lung Cancer Clinical Quality Registry (ANZLCR)
- Author
-
Stirling, R., primary, Smith, S., additional, Brand, M., additional, Harden, S., additional, Briggs, L., additional, Leigh, L., additional, Brims, F., additional, Brooke, M., additional, Brunelli, V., additional, Chia, C., additional, Dawkins, P., additional, Lawrenson, R., additional, Duffy, M., additional, Evans, S., additional, Leong, T., additional, Marshall, H., additional, Patel, D., additional, Pavlakis, N., additional, Philip, J., additional, Rankin, N., additional, Singhal, N., additional, Stone, E., additional, Tay, R., additional, Vinod, S., additional, Windsor, M., additional, Wright, G., additional, Leong, D., additional, and Zalcberg, J., additional
- Published
- 2022
- Full Text
- View/download PDF
10. P2.04B.05 Engaging Culturally and Linguistically Diverse Communities to Prepare for Lung Cancer Screening Implementation in Australia
- Author
-
York, S., Yap, M.L., Rhee, J., Pitts, L., Troiani, J.P., Stanoevska, B., Harrison, N., Dodd, R., McWilliams, A., Marshall, H., Stone, E., and Rankin, N.
- Published
- 2024
- Full Text
- View/download PDF
11. MA04.09 An International Qualitative Study of Healthcare Provider Perspectives of the Psychosocial Impacts and Barriers to Lung Cancer Screening
- Author
-
McFadden, K., Nickel, B., Houssami, N., Rankin, N., and Dodd, R.
- Published
- 2024
- Full Text
- View/download PDF
12. Predictors of Academic Performance: National Senior Certificate versus National Benchmark Test
- Author
-
Rankin, N., Schoer, V., Sebastiao, C., and van Walbeek, C.
- Abstract
This article considers students' performance in an identical Economics test at two universities to investigate the predictive power of the NBT against that of Mathematics in the National Senior Certificate (NSC) exam. We find that, on average, both NBT and NSC results are useful predictors of performance in first year Economics. However, for students whose NSC Mathematics marks are close to the minimum admission requirements, the NBT scores (especially in Quantitative and Academic Literacy) are better measures of academic potential. Thus, an admission criterion based on NSC marks alone may exclude students with the academic potential to pass university courses, while it may admit students that are not sufficiently prepared for university studies. Our findings suggest that the NBT should not be used as an alternative to the NSC, but as a complement for admission and correct placement of lower performing applicants. (Contains 4 figures, 8 tables and 1 note.)
- Published
- 2012
13. A comprehensive index of implementation strategies to embed smoking cessation interventions into health services: Findings from a systematic review.
- Author
-
Ugalde A., White V., Rankin N., Paul C., Segan C., Aranda S., Shee A.W., Hutchinson A., Livingston T., Ugalde A., White V., Rankin N., Paul C., Segan C., Aranda S., Shee A.W., Hutchinson A., and Livingston T.
- Abstract
Background: Smoking cessation after a cancer diagnosis reduces risk of hospital readmission, improves recovery and reduces the risk of death. evidence-based policies recommend hospital admission is an ideal time to deliver smoking cessation interventions. However, hospital-based interventions are not well implemented. Implementation strategies are the techniques used to embed a new model of care into practice. Sharing knowledge about implementation strategies that have been applied in smoking cessation interventions in hospital-based settings is needed. Aim(s): This presentation will detail a comprehensive index of implementation strategies that have been applied to embed smoking cessation interventions into health services, as identified in a systematic review. Methods : We searched CINAHL Complete, Embase, MEDLINE Complete and PsycInfo using concepts smoking cessation, hospitals and implementation from 2010 to 2020, including all study designs. Data were extracted on study characteristics and implementation strategies, assessed according to four defined managerial functions: planning, organising, leading, monitoring. Results : A total of 14,287 original records were identified and screened, resulting in 63 included papers from 56 studies. Forty-two different implementation strategies were identified. Seventeen of these were categorised under Planning, including stakeholder consultation/engagement (n = 14 studies;25%), executive/senior leadership buy-in (n = 10;18%) and piloting (n = 10;18%). Twenty-one studies (38%) had no planning activities. Organising encompassed 10 strategies, the most common being certification of staff (n = 7, 13%), though most studies had no organisation implementation strategies (n = 31;55%). All studies used a Leading implementation strategy, most commonly training (54 studies;96%), and audit was the most common for Monitoring (n = 29 studies;52%). Results indicate multi-strategic approaches are recommended. Conclusions and Implications
- Published
- 2022
14. Staff perspectives on the feasibility of a clinical pathway for anxiety and depression in cancer care, and mid-implementation adaptations.
- Author
-
Butow, P, Shepherd, HL, Cuddy, J, Rankin, N, Harris, M, He, S, Grimison, P, Girgis, A, Faris, M, ADAPT Program Group, Shaw, J, Butow, P, Shepherd, HL, Cuddy, J, Rankin, N, Harris, M, He, S, Grimison, P, Girgis, A, Faris, M, ADAPT Program Group, and Shaw, J
- Abstract
BACKGROUND: Clinical pathways (CPs) are intended to standardise and improve care but do not always produce positive outcomes, possibly because they were not adapted to suit the specific context in which they were enacted. This qualitative study aimed to explore staff perspectives of implementation of a CP for routine screening, assessment, referral and management of anxiety and depression (the ADAPT CP) for patients with cancer, focussing on perceived feasibility of the CP and negotiated adaptations made during the implementation phase. METHODS: The ADAPT CP was implemented in 12 urban and regional oncology services in Australia. Services were randomised to receive core versus enhanced implementation strategies. Core sites received support until implementation commencement and could access progress reports. Enhanced sites received proactive, ongoing support during the 12-month implementation. Purposively selected staff were interviewed prior to implementation (n = 88) and 6 months later, half-way through the implementation period (n = 89). Monthly meetings with lead multi-disciplinary teams at the eight enhanced sites were recorded. Data were thematically analysed. RESULTS: Six overarching themes were identified: ADAPT is of high value; timing for introducing the CP and screening is difficult; online screening is challenging; a burden too much; no-one to refer patients to; and micro-logistics are key. While early screening was deemed desirable, diverse barriers meant this was complex, with adaptations made to time and screening location. Online screening prompted by email, seen as time-saving and efficient, also proved unsuccessful in some services, with adaptations made to in-clinic or phone screening, or repeated email reminders. Staff negative attitudes to ADAPT, time constraints, and perceived poor fit of ADAPT to work roles and flows, all impacted implementation, with key tasks often devolving to a few key individuals. Nevertheless, services remained committed
- Published
- 2022
15. Development of an Australia and New Zealand Lung Cancer Clinical Quality Registry: a protocol paper
- Author
-
Smith, S, Brand, M, Harden, S, Briggs, L, Leigh, L, Brims, F, Brooke, M, Brunelli, VN, Chia, C, Dawkins, P, Lawrenson, R, Duffy, M, Evans, S, Leong, T, Marshall, H, Patel, D, Pavlakis, N, Philip, J, Rankin, N, Singhal, N, Stone, E, Tay, R, Vinod, S, Windsor, M, Wright, GM, Leong, D, Zalcberg, J, Stirling, RG, Smith, S, Brand, M, Harden, S, Briggs, L, Leigh, L, Brims, F, Brooke, M, Brunelli, VN, Chia, C, Dawkins, P, Lawrenson, R, Duffy, M, Evans, S, Leong, T, Marshall, H, Patel, D, Pavlakis, N, Philip, J, Rankin, N, Singhal, N, Stone, E, Tay, R, Vinod, S, Windsor, M, Wright, GM, Leong, D, Zalcberg, J, and Stirling, RG
- Abstract
INTRODUCTION: Lung cancer is the leading cause of cancer mortality, comprising the largest national cancer disease burden in Australia and New Zealand. Regional reports identify substantial evidence-practice gaps, unwarranted variation from best practice, and variation in processes and outcomes of care between treating centres. The Australia and New Zealand Lung Cancer Registry (ANZLCR) will be developed as a Clinical Quality Registry to monitor the safety, quality and effectiveness of lung cancer care in Australia and New Zealand. METHODS AND ANALYSIS: Patient participants will include all adults >18 years of age with a new diagnosis of non-small-cell lung cancer (NSCLC), SCLC, thymoma or mesothelioma. The ANZLCR will register confirmed diagnoses using opt-out consent. Data will address key patient, disease, management processes and outcomes reported as clinical quality indicators. Electronic data collection facilitated by local data collectors and local, state and federal data linkage will enhance completeness and accuracy. Data will be stored and maintained in a secure web-based data platform overseen by registry management. Central governance with binational representation from consumers, patients and carers, governance, administration, health department, health policy bodies, university research and healthcare workers will provide project oversight. ETHICS AND DISSEMINATION: The ANZLCR has received national ethics approval under the National Mutual Acceptance scheme. Data will be routinely reported to participating sites describing performance against measures of agreed best practice and nationally to stakeholders including federal, state and territory departments of health. Local, regional and (bi)national benchmarks, augmented with online dashboard indicator reporting will enable local targeting of quality improvement efforts.
- Published
- 2022
16. WHICH STRATEGIES ARE EFFECTIVE IN CHANGING HEALTH PROFESSIONAL BEHAVIOR ASSOCIATED WITH NON-PHARMACOLOGICAL, NON-SURGICAL MANAGEMENT OF OSTEOARTHRITIS AND SPINAL PAIN? A SYSTEMATIC REVIEW.
- Author
-
Eyles, J.P., primary, Ferreira, M.L., additional, Rankin, N., additional, Salles, A., additional, March, M.K., additional, Ferreira, P.H., additional, Sherrington, C., additional, Hunter, D.J., additional, and Bowden, J.L., additional
- Published
- 2022
- Full Text
- View/download PDF
17. Staff perspectives on the feasibility of a clinical pathway for anxiety and depression in cancer care, and mid-implementation adaptations
- Author
-
Butow, P, Shepherd, HL, Cuddy, J, Rankin, N, Harris, M, He, S, Grimison, P, Girgis, A, Faris, M, ADAPT Program Group, and Shaw, J
- Subjects
Depression ,Neoplasms ,Health Policy & Services ,Critical Pathways ,Feasibility Studies ,Humans ,0807 Library and Information Studies, 1110 Nursing, 1117 Public Health and Health Services ,Anxiety ,Anxiety Disorders - Abstract
BACKGROUND: Clinical pathways (CPs) are intended to standardise and improve care but do not always produce positive outcomes, possibly because they were not adapted to suit the specific context in which they were enacted. This qualitative study aimed to explore staff perspectives of implementation of a CP for routine screening, assessment, referral and management of anxiety and depression (the ADAPT CP) for patients with cancer, focussing on perceived feasibility of the CP and negotiated adaptations made during the implementation phase. METHODS: The ADAPT CP was implemented in 12 urban and regional oncology services in Australia. Services were randomised to receive core versus enhanced implementation strategies. Core sites received support until implementation commencement and could access progress reports. Enhanced sites received proactive, ongoing support during the 12-month implementation. Purposively selected staff were interviewed prior to implementation (n = 88) and 6 months later, half-way through the implementation period (n = 89). Monthly meetings with lead multi-disciplinary teams at the eight enhanced sites were recorded. Data were thematically analysed. RESULTS: Six overarching themes were identified: ADAPT is of high value; timing for introducing the CP and screening is difficult; online screening is challenging; a burden too much; no-one to refer patients to; and micro-logistics are key. While early screening was deemed desirable, diverse barriers meant this was complex, with adaptations made to time and screening location. Online screening prompted by email, seen as time-saving and efficient, also proved unsuccessful in some services, with adaptations made to in-clinic or phone screening, or repeated email reminders. Staff negative attitudes to ADAPT, time constraints, and perceived poor fit of ADAPT to work roles and flows, all impacted implementation, with key tasks often devolving to a few key individuals. Nevertheless, services remained committed to the ADAPT CP, and worked hard to create, review and adapt strategies to address challenges to optimise success. CONCLUSIONS: This study demonstrates the interactive nature of health service change, with staff actively engaging with, forming views on, and problem-solving adaptations of the ADAPT CP to overcome barriers. Obtaining staff feedback is critical to ensure health service change is sustainable, meaningful and achieves its promise of improving patient outcomes. TRIAL REGISTRATION: The study was registered prospectively with the ANZCTR on 22/3/2017. Trial ID ACTRN12617000411347.
- Published
- 2021
18. Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations
- Author
-
Luckett, T., King, M.T., Butow, P.N., Oguchi, M., Rankin, N., Price, M.A., Hackl, N.A., and Heading, G.
- Published
- 2011
- Full Text
- View/download PDF
19. The effect of metformin on circulating amino acids in the Carotid Atherosclerosis: Metformin for insulin Resistance (CAMERA) trial reveals a novel effect on four amino acids: A33 (P165)
- Author
-
Rankin, N, Lloyd, S M, Sattar, N, Welsh, P, Holman, R R, Kangas, A J, Soininen, P, Ala-Korpela, M, and Preiss, D
- Published
- 2015
20. Debt Policy under Fixed and Flexible Prices
- Author
-
Rankin, N.
- Published
- 1986
21. Commentary on ‘Exclusion rates in randomized trials of treatments for physical conditions: a systematic review’
- Author
-
Ugalde, Anna, Kiss, Nicole, Livingston, Patricia, Rankin, N, Ugalde, Anna, Kiss, Nicole, Livingston, Patricia, and Rankin, N
- Published
- 2021
22. Care plus study: a multi-site implementation of early palliative care in routine practice to improve health outcomes and reduce hospital admissions for people with advanced cancer: a study protocol
- Author
-
Philip, J, Le Gautier, R, Collins, A, Nowak, AK, Le, B, Crawford, GB, Rankin, N, Krishnasamy, M, Mitchell, G, McLachlan, S-A, IJzerman, M, Hudson, R, Rischin, D, Sousa, TV, Sundararajan, V, Philip, J, Le Gautier, R, Collins, A, Nowak, AK, Le, B, Crawford, GB, Rankin, N, Krishnasamy, M, Mitchell, G, McLachlan, S-A, IJzerman, M, Hudson, R, Rischin, D, Sousa, TV, and Sundararajan, V
- Abstract
BACKGROUND: Current international consensus is that 'early' referral to palliative care services improves cancer patient and family carer outcomes. In practice, however, these referrals are not routine. An approach which directly addresses identified barriers to early integration of palliative care is required. This protocol details a trial of a standardized model of early palliative care (Care Plus) introduced at key defined, disease-specific times or transition points in the illness for people with cancer. Introduced as a 'whole of system' practice change for identified advanced cancers, the key outcomes of interest are population health service use change. The aims of the study are to examine the effect of Care Plus implementation on (1) acute hospitalisation days in the last 3 months of life; (2) timeliness of access to palliative care; (3) quality and (4) costs of end of life care; and (5) the acceptability of services for people with advanced cancer. METHODS: Multi-site stepped wedge implementation trial testing usual care (control) versus Care Plus (practice change). The design stipulates 'control' periods when usual care is observed, and the process of implementing Care Plus which includes phases of planning, engagement, practice change and evaluation. During the practice change phase, all patients with targeted advanced cancers reaching the transition point will, by default, receive Care Plus. Health service utilization and unit costs before and after implementation will be collated from hospital records, and state and national health service administrative datasets. Qualitative data from patients, consumers and clinicians before and after practice change will be gathered through interviews and focus groups. DISCUSSION: The study outcomes will detail the impact and acceptability of the standardized integration of palliative care as a practice change, including recommendations for ongoing sustainability and broader implementation. TRIAL REGISTRATION: Austral
- Published
- 2021
23. Commentary on 'Exclusion rates in randomized trials of treatments for physical conditions: a systematic review'.
- Author
-
Ugalde, A, Kiss, N, Livingston, PM, Rankin, N, Ugalde, A, Kiss, N, Livingston, PM, and Rankin, N
- Published
- 2021
24. Evidence for interventions to improve psychological outcomes in people with head and neck cancer: a systematic review of the literature
- Author
-
Luckett, T., Britton, B., Clover, K., and Rankin, N. M.
- Published
- 2011
- Full Text
- View/download PDF
25. P09.47 Implementation of Lung Cancer Multidisciplinary Care: A Rapid Review of Evidence-Practice Gaps
- Author
-
Rankin, N., primary, Fradgley, E., additional, and Barnes, D., additional
- Published
- 2021
- Full Text
- View/download PDF
26. P41.07 Lung Cancer Screening: What is the State of the Evidence about Implementation?
- Author
-
Rankin, N., primary, Mcgregor, D., additional, Donnelly, C., additional, Cust, A., additional, De Abreu Lourenco, R., additional, Van Dort, B., additional, Broome, K., additional, Sharman, A., additional, and Stone, E., additional
- Published
- 2021
- Full Text
- View/download PDF
27. Optimizing lung cancer MDT data for maximum clinical impact-a scoping literature review
- Author
-
Stone, E, Rankin, N, Currow, D, Fong, KM, Phillips, JL, and Shaw, T
- Subjects
1103 Clinical Sciences, 1112 Oncology and Carcinogenesis - Abstract
Multidisciplinary care in is widely recommended as best practice for lung cancer in many countries and jurisdictions. A number of studies suggest multidisciplinary care benefits patient outcomes, with analyses based on a range of data sources including national, state and local registries as well as multidisciplinary team meeting (MDT)-based data collections, often focused on different questions depending on data sources. MDT data collection and linkage are not standardized and not routine although data collection and feedback are specifically recommended by at least one statutory body. We performed a scoping review of current evidence for lung cancer MDT data collection and analysis, to identify discrete strategies through illustrative examples and to make recommendations for future approaches. Thirteen studies were identified that presented lung cancer MDT-related clinical outcomes, three included MDTs from multiple tumour streams while 10 studies focussed on lung cancer MDT meetings. Eleven studies measured the effect of MDT discussion on clinical outcomes of which eight were positive. Data sources included MDT records (3 studies), medical or hospital records (3 studies), institutional registries (5 studies) and state or national administrative datasets (6 studies), with some overlap. Examples of studies based on different data sources (local MDT, institutional registry, national registry) exemplified the different types of clinical research questions appropriate for each data source. While MDT data collection is not well-defined, the importance of clinical audit and data feedback and the potential for real-time analysis to improve outcomes deserve further investigation. Optimized datasets and linkage strategies are likely to maximize benefits for patients.
- Published
- 2020
28. Disability, psychological distress and quality of life in relation to cancer diagnosis and cancer type: population-based Australian study of 22,505 cancer survivors and 244,000 people without cancer.
- Author
-
Joshy, G, Thandrayen, J, Koczwara, B, Butow, P, Laidsaar-Powell, R, Rankin, N, Canfell, K, Stubbs, J, Grogan, P, Bailey, L, Yazidjoglou, A, Banks, E, Joshy, G, Thandrayen, J, Koczwara, B, Butow, P, Laidsaar-Powell, R, Rankin, N, Canfell, K, Stubbs, J, Grogan, P, Bailey, L, Yazidjoglou, A, and Banks, E
- Abstract
BACKGROUND: Improved survival means that cancer is increasingly becoming a chronic disease. Understanding and improving functional outcomes are critical to optimising survivorship. We quantified physical and mental health-related outcomes in people with versus without cancer, according to cancer type. METHODS: Questionnaire data from an Australian population-based cohort study (45 and Up Study (n = 267,153)) were linked to cancer registration data to ascertain cancer diagnoses up to enrolment. Modified Poisson regression estimated age- and sex-adjusted prevalence ratios (PRs) for adverse person-centred outcomes-severe physical functional limitations (disability), moderate/high psychological distress and fair/poor quality of life (QoL)-in participants with versus without cancer, for 13 cancer types. RESULTS: Compared to participants without cancer (n = 244,000), cancer survivors (n = 22,505) had greater disability (20.6% versus 12.6%, respectively, PR = 1.28, 95%CI = (1.25-1.32)), psychological (22.2% versus 23.5%, 1.05 (1.02-1.08)) and poor/fair QoL (15.2% versus 10.2%; 1.28 (1.24-1.32)). The outcomes varied by cancer type, being worse for multiple myeloma (PRs versus participants without cancer for disability 3.10, 2.56-3.77; distress 1.53, 1.20-1.96; poor/fair QoL 2.40, 1.87-3.07), lung cancer (disability 2.81, 2.50-3.15; distress 1.67, 1.46-1.92; poor/fair QoL 2.53, 2.21-2.91) and non-Hodgkin's lymphoma (disability 1.56, 1.37-1.78; distress 1.20, 1.05-1.36; poor/fair QoL 1.66, 1.44-1.92) and closer to those in people without cancer for breast cancer (disability 1.23, 1.16-1.32; distress 0.95, 0.90-1.01; poor/fair QoL 1.15, 1.05-1.25), prostate cancer (disability 1.11, 1.04-1.19; distress 1.09, 1.02-1.15; poor/fair QoL 1.15, 1.08-1.23) and melanoma (disability 1.02, 0.94-1.10; distress 0.96, 0.89-1.03; poor/fair QoL 0.92, 0.83-1.01). Outcomes were worse with recent diagnosis and treatment and advanced stage. Physical disability in cancer survivors was greater in a
- Published
- 2020
29. Book reviews
- Author
-
Quiggin, J., Nurmi, H., Cason, T. N., Färe, R., Greiner, A., Aharoni, Y., Rankin, N., Ward, M., Burkhauser, R. V., and Tullock, G.
- Published
- 2000
- Full Text
- View/download PDF
30. Low sleep and low socioeconomic status predict high body mass index: a 4-year longitudinal study of Australian schoolchildren
- Author
-
OʼDea, J. A., Dibley, M. J., and Rankin, N. M.
- Published
- 2012
- Full Text
- View/download PDF
31. Fiscal policy in quantity-constrained equilibrium
- Author
-
Rankin, N.
- Subjects
330 ,Economic policy - Published
- 1984
32. Sensitivity to spatial frequency and orientation content is not specific to face perception
- Author
-
Williams, Rankin N., Willenbockel, Verena, and Gauthier, Isabel
- Published
- 2009
- Full Text
- View/download PDF
33. Posters
- Author
-
Rodríguez, A. López, Sánchez, L. López, Julià, J. A., Lonĉar-Stoiiliković, D., Stojiljković, M. P., Marković, M., Djordjević, B., Boŝković, D., Marenović, S., Marenović, T., Jovanović, N. C., Leino, K., Nunes, S., Yalta, P., Takala, J., Stathoulopoulou, F., Pavlou, E., Delaki, Ch., Thymianou, H., Loannidou, E., Jooste, C. A., Mustoe, J. E., Bradbury, W., Collee, G. G., Giles, L. J., Bass, S. P., Stockwell, M. A., Brunner, G. A., Lueger, A., Kaufmann, P., Smolle, K. H., Krejs, G. J., Rafkin, H., Hadbavny, A., Hoyt, J., Williams, R., Seakins, P., Rankin, N., Smith, T., Galler, D., Arag~äo, I., Soares, M. E., Bastos, M. L., Lopes, M., Mackenzie, S. J., Grant, I. S., Tourkochoriti, L., Karabatsos, E., Zidianakis, B., Filippatos, G., Boutzouka, E., Baltopoulos, G., Berkenstadt, H., Segal, E., Mayan, H., Almog, S., Dani, S., Perel, A., Ezra, D., Hachenberg, T., Karmann, S., Thomas, H., Pfeiffer, B., Gründling, M., Wendt, M., Wray, G., Skinner, R., Rees, D., Watson, D., Margarson, M., Noormohamed, F., and Soni, N.
- Published
- 1996
- Full Text
- View/download PDF
34. Introduction
- Author
-
RANKIN, N, primary
- Published
- 2003
- Full Text
- View/download PDF
35. Consensus minimum data set for lung cancer multidisciplinary teams: Results of a Delphi process
- Author
-
Stone E, Rankin N, Phillips J, Fong K, Currow D, Miller A, Largey G, Zielinski R, Flynn P, and Shaw T
- Subjects
Patient Care Team ,Benchmarking ,Lung Neoplasms ,Consensus ,Delphi Technique ,Cancer Type - Lung Cancer ,Data Collection ,Surveys and Questionnaires ,Respiratory System ,Clinical Decision-Making ,Australia ,Humans ,Group Processes - Abstract
© 2018 Asian Pacific Society of Respirology Background and objective: While multidisciplinary team (MDT) care in lung cancer is widely practiced, there are few guidelines for MDT on best data collection strategies. MDT meetings need ready access to information for the provision of optimal treatment recommendations (the primary purpose of the meeting), audit of team performance and benchmarking. This study aimed to develop a practical data set designed for these goals through a recognized consensus process with health professionals who participate in formal MDT settings. Methods: A modified Delphi process with three iterations (two surveys and one consensus conference) was carried out involving over 100 Australian lung cancer MDT health professionals. Results: In total, 122 lung cancer MDT health professionals responded to the Round 1 survey from over 350 invitees. Of the 122, 98 were available for invitation to Round 2. Of 98, 52 (53%) invitees responded to the Round 2 survey. After two rounds, 51 data elements across 8 domains (patient demographics, risk factors, biopsy data, staging, timeliness, treatment, follow-up and patient selection) achieved consensus, defined as 80% agreement. For Round 3, 33 MDT lead clinicians were invited to participate in a consensus conference. Of 33, 14 (42%) invitees distilled the 47 data elements into 23 elements across 8 domains to address the study objectives. Conclusion: A practical data set for lung cancer MDT to use for optimal treatment recommendations and to evaluate team performance was developed through recognized consensus methodology. Access to streamlined, relevant and feasible data collection strategies may improve MDT decision-making, audit of team performance and facilitate benchmarking.
- Published
- 2018
36. Health services costs for cancer care in Australia: Estimates from the 45 and Up Study
- Author
-
Goldsbury DE, Yap S, Weber MF, Veerman L, Rankin N, Banks E, Canfell K, and O'Connell DL
- Subjects
Cancer Type - All Cancers combined - Abstract
Background Cancer care represents a substantial and rapidly rising healthcare cost in Australia. Our aim was to provide accurate population-based estimates of the health services cost of cancer care using large-scale linked patient-level data. Methods We analysed data for incident cancers diagnosed 2006–2010 and followed to 2014 among 266,793 eligible participants in the 45 and Up Study. Health system costs included Medicare and pharmaceutical claims, inpatient hospital episodes and emergency department presentations. Costs for cancer cases and matched cancer-free controls were compared, to estimate monthly/annual excess costs of cancer care by cancer type, before and after diagnosis and by phase of care (initial, continuing, terminal). Total costs incurred in 2013 were also estimated for all people diagnosed in Australia 2009–2013. Results 7624 participants diagnosed with cancer were matched with up to three controls. The mean excess cost of care per case was AUD$1,622 for the year before diagnosis, $33,944 for the first year post-diagnosis and $8,796 for the second year post-diagnosis, with considerable variation by cancer type. Mean annual cost after the initial treatment phase was $4,474/case and the mean cost for the last year of life was $49,733/case. In 2013 the cost for cancers among people in Australia diagnosed during 2009–2013 was ~$6.3billion (0.4% of Gross Domestic Product; $272 per capita), with the largest costs for colorectal cancer ($1.1billion), breast cancer ($0.8billion), lung cancer ($0.6billion) and prostate cancer ($0.5billion). Conclusions The cost of cancer care is substantial and varies by cancer type and time since diagnosis. These findings emphasise the economic importance of effective primary and secondary cancer prevention strategies.
- Published
- 2018
37. Nuclear magnetic resonance‐based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation:results from PROSPER and FINRISK 1997
- Author
-
Delles, C. (Christian), Rankin, N. J. (Naomi J.), Boachie, C. (Charles), McConnachie, A. (Alex), Ford, I. (Ian), Kangas, A. (Antti), Soininen, P. (Pasi), Trompet, S. (Stella), Mooijaart, S. P. (Simon P.), Jukema, J. W. (J. Wouter), Zannad, F. (Faiez), Ala‐Korpela, M. (Mika), Salomaa, V. (Veikko), Havulinna, A. S. (Aki S.), Welsh, P. (Paul), Würtz, P. (Peter), and Sattar, N. (Naveed)
- Subjects
Phenylalanine ,FINRISK ,Metabolomics ,Heart failure ,PROSPER ,Advanced lipoprotein profiling - Abstract
Aims: We investigated the association between quantified metabolite, lipid and lipoprotein measures and incident heart failure hospitalisation (HFH) in the elderly, and examined whether circulating metabolic measures improve HFH prediction. Methods and results: Overall, 80 metabolic measures from the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) trial were measured by proton nuclear magnetic resonance spectroscopy (n = 5341; 182 HFH events during 2.7‐year follow‐up). We repeated the work in FINRISK 1997 (n = 7330; 133 HFH events during 5‐year follow‐up). In PROSPER, the circulating concentrations of 13 metabolic measures were found to be significantly different in those who were later hospitalised for heart failure after correction for multiple comparisons. These included creatinine, phenylalanine, glycoprotein acetyls, 3‐hydroxybutyrate, and various high‐density lipoprotein measures. In Cox models, two metabolites were associated with risk of HFH after adjustment for clinical risk factors and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP): phenylalanine [hazard ratio (HR) 1.29, 95% confidence interval (CI) 1.10–1.53; P = 0.002] and acetate (HR 0.81, 95% CI 0.68–0.98; P = 0.026). Both were retained in the final model after backward elimination. Compared to a model with established risk factors and NT‐proBNP, this model did not improve the C‐index but did improve the overall continuous net reclassification index (NRI 0.21; 95% CI 0.06–0.35; P = 0.007) due to improvement in classification of non‐cases (NRI 0.14; 95% CI 0.12–0.17; P
- Published
- 2018
38. An in vitro system for Doppler ultrasound flow studies in the stenosed carotid artery bifurcation
- Author
-
Poepping, Tamie L., Nikolov, N., Rankin, N., Lee, Mark, and Holdsworth, David W.
- Published
- 2002
- Full Text
- View/download PDF
39. Consensus minimum data set for lung cancer multidisciplinary teams: Results of a Delphi process.
- Author
-
Largey G., Miller A., Zielinski R., Shaw T., Flynn P., Stone E., Rankin N., Phillips J., Fong K., Currow D.C., Largey G., Miller A., Zielinski R., Shaw T., Flynn P., Stone E., Rankin N., Phillips J., Fong K., and Currow D.C.
- Abstract
Background and objective: While multidisciplinary team (MDT) care in lung cancer is widely practiced, there are few guidelines for MDT on best data collection strategies. MDT meetings need ready access to information for the provision of optimal treatment recommendations (the primary purpose of the meeting), audit of team performance and benchmarking. This study aimed to develop a practical data set designed for these goals through a recognized consensus process with health professionals who participate in formal MDT settings. Method(s): A modified Delphi process with three iterations (two surveys and one consensus conference) was carried out involving over 100 Australian lung cancer MDT health professionals. Result(s): In total, 122 lung cancer MDT health professionals responded to the Round 1 survey from over 350 invitees. Of the 122, 98 were available for invitation to Round 2. Of 98, 52 (53%) invitees responded to the Round 2 survey. After two rounds, 51 data elements across 8 domains (patient demographics, risk factors, biopsy data, staging, timeliness, treatment, follow-up and patient selection) achieved consensus, defined as 80% agreement. For Round 3, 33 MDT lead clinicians were invited to participate in a consensus conference. Of 33, 14 (42%) invitees distilled the 47 data elements into 23 elements across 8 domains to address the study objectives. Conclusion(s): A practical data set for lung cancer MDT to use for optimal treatment recommendations and to evaluate team performance was developed through recognized consensus methodology. Access to streamlined, relevant and feasible data collection strategies may improve MDT decision-making, audit of team performance and facilitate benchmarking.Copyright © 2018 Asian Pacific Society of Respirology
- Published
- 2018
40. Health services costs for cancer care in Australia: Estimates from the 45 and Up Study.
- Author
-
Paci, E, Goldsbury, DE, Yap, S, Weber, MF, Veerman, L, Rankin, N, Banks, E, Canfell, K, O'Connell, DL, Paci, E, Goldsbury, DE, Yap, S, Weber, MF, Veerman, L, Rankin, N, Banks, E, Canfell, K, and O'Connell, DL
- Abstract
BACKGROUND: Cancer care represents a substantial and rapidly rising healthcare cost in Australia. Our aim was to provide accurate population-based estimates of the health services cost of cancer care using large-scale linked patient-level data. METHODS: We analysed data for incident cancers diagnosed 2006-2010 and followed to 2014 among 266,793 eligible participants in the 45 and Up Study. Health system costs included Medicare and pharmaceutical claims, inpatient hospital episodes and emergency department presentations. Costs for cancer cases and matched cancer-free controls were compared, to estimate monthly/annual excess costs of cancer care by cancer type, before and after diagnosis and by phase of care (initial, continuing, terminal). Total costs incurred in 2013 were also estimated for all people diagnosed in Australia 2009-2013. RESULTS: 7624 participants diagnosed with cancer were matched with up to three controls. The mean excess cost of care per case was AUD$1,622 for the year before diagnosis, $33,944 for the first year post-diagnosis and $8,796 for the second year post-diagnosis, with considerable variation by cancer type. Mean annual cost after the initial treatment phase was $4,474/case and the mean cost for the last year of life was $49,733/case. In 2013 the cost for cancers among people in Australia diagnosed during 2009-2013 was ~$6.3billion (0.4% of Gross Domestic Product; $272 per capita), with the largest costs for colorectal cancer ($1.1billion), breast cancer ($0.8billion), lung cancer ($0.6billion) and prostate cancer ($0.5billion). CONCLUSIONS: The cost of cancer care is substantial and varies by cancer type and time since diagnosis. These findings emphasise the economic importance of effective primary and secondary cancer prevention strategies.
- Published
- 2018
41. Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial.
- Author
-
Welsh, P, Rankin, N, Li, Q, Mark, PB, Würtz, P, Ala-Korpela, M, Marre, M, Poulter, N, Hamet, P, Chalmers, J, Woodward, M, Sattar, N, Welsh, P, Rankin, N, Li, Q, Mark, PB, Würtz, P, Ala-Korpela, M, Marre, M, Poulter, N, Hamet, P, Chalmers, J, Woodward, M, and Sattar, N
- Abstract
AIMS/HYPOTHESES: We aimed to quantify the association of individual circulating amino acids with macrovascular disease, microvascular disease and all-cause mortality in individuals with type 2 diabetes. METHODS: We performed a case-cohort study (N = 3587), including 655 macrovascular events, 342 microvascular events (new or worsening nephropathy or retinopathy) and 632 all-cause mortality events during follow-up, in a secondary analysis of the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study. For this study, phenylalanine, isoleucine, glutamine, leucine, alanine, tyrosine, histidine and valine were measured in stored plasma samples by proton NMR metabolomics. Hazard ratios were modelled per SD increase in each amino acid. RESULTS: In models investigating associations and potential mechanisms, after adjusting for age, sex and randomised treatment, phenylalanine was positively, and histidine inversely, associated with macrovascular disease risk. These associations were attenuated to the null on further adjustment for extended classical risk factors (including eGFR and urinary albumin/creatinine ratio). After adjustment for extended classical risk factors, higher tyrosine and alanine levels were associated with decreased risk of microvascular disease (HR 0.78; 95% CI 0.67, 0.91 and HR 0.86; 95% CI 0.76, 0.98, respectively). Higher leucine (HR 0.79; 95% CI 0.69, 0.90), histidine (HR 0.89; 95% CI 0.81, 0.99) and valine (HR 0.79; 95% CI 0.70, 0.88) levels were associated with lower risk of mortality. Investigating the predictive ability of amino acids, addition of all amino acids to a risk score modestly improved classification of participants for macrovascular (continuous net reclassification index [NRI] +35.5%, p < 0.001) and microvascular events (continuous NRI +14.4%, p = 0.012). CONCLUSIONS/INTERPRETATION: We report distinct associations between circulating amino acids and risk of different major c
- Published
- 2018
42. Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment
- Author
-
Sliz, E. (Eeva), Kettunen, J. (Johannes), Holmes, M. V. (Michael V.), Williams, C. O. (Clare Oliver), Boachie, C. (Charles), Wang, Q. (Qin), Maennikkoe, M. (Minna), Sebert, S. (Sylvain), Walters, R. (Robin), Lin, K. (Kuang), Millwood, I. Y. (Iona Y.), Clarke, R. (Robert), Li, L. (Liming), Rankin, N. (Naomi), Welsh, P. (Paul), Delles, C. (Christian), Jukema, J. W. (J. Wouter), Trompet, S. (Stella), Ford, I. (Ian), Perola, M. (Markus), Salomaa, V. (Veikko), Jaervelin, M.-R. (Marjo-Riitta), Chen, Z. (Zhengming), Lawlor, D. A. (Debbie A.), Ala-Korpela, M. (Mika), Danesh, J. (John), Davey Smith, G. (George), Sattar, N. (Naveed), Butterworth, A. (Adam), Wuertz, P. (Peter), Sliz, E. (Eeva), Kettunen, J. (Johannes), Holmes, M. V. (Michael V.), Williams, C. O. (Clare Oliver), Boachie, C. (Charles), Wang, Q. (Qin), Maennikkoe, M. (Minna), Sebert, S. (Sylvain), Walters, R. (Robin), Lin, K. (Kuang), Millwood, I. Y. (Iona Y.), Clarke, R. (Robert), Li, L. (Liming), Rankin, N. (Naomi), Welsh, P. (Paul), Delles, C. (Christian), Jukema, J. W. (J. Wouter), Trompet, S. (Stella), Ford, I. (Ian), Perola, M. (Markus), Salomaa, V. (Veikko), Jaervelin, M.-R. (Marjo-Riitta), Chen, Z. (Zhengming), Lawlor, D. A. (Debbie A.), Ala-Korpela, M. (Mika), Danesh, J. (John), Davey Smith, G. (George), Sattar, N. (Naveed), Butterworth, A. (Adam), and Wuertz, P. (Peter)
- Abstract
Background: Both statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors lower blood low-density lipoprotein cholesterol levels to reduce risk of cardiovascular events. To assess potential differences between metabolic effects of these 2 lipid-lowering therapies, we performed detailed lipid and metabolite profiling of a large randomized statin trial and compared the results with the effects of genetic inhibition of PCSK9, acting as a naturally occurring trial. Methods: Two hundred twenty-eight circulating metabolic measures were quantified by nuclear magnetic resonance spectroscopy, including lipoprotein subclass concentrations and their lipid composition, fatty acids, and amino acids, for 5359 individuals (2659 on treatment) in the PROSPER (Prospective Study of Pravastatin in the Elderly at Risk) trial at 6 months postrandomization. The corresponding metabolic measures were analyzed in 8 population cohorts (N=72 185) using PCSK9 rs11591147 as an unconfounded proxy to mimic the therapeutic effects of PCSK9 inhibitors. Results: Scaled to an equivalent lowering of low-density lipoprotein cholesterol, the effects of genetic inhibition of PCSK9 on 228 metabolic markers were generally consistent with those of statin therapy (R²=0.88). Alterations in lipoprotein lipid composition and fatty acid distribution were similar. However, discrepancies were observed for very-low-density lipoprotein lipid measures. For instance, genetic inhibition of PCSK9 had weaker effects on lowering of very-low-density lipoprotein cholesterol compared with statin therapy (54% versus 77% reduction, relative to the lowering effect on low-density lipoprotein cholesterol; P=2×10⁻⁷ for heterogeneity). Genetic inhibition of PCSK9 showed no significant effects on amino acids, ketones, or a marker of inflammation (GlycA), whereas statin treatment weakly lowered GlycA levels. Conclusions: Genetic inhibition of PCSK9 had similar metabolic effects to statin therapy on detaile
- Published
- 2018
43. Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes:results from the ADVANCE trial
- Author
-
Welsh, P. (Paul), Rankin, N. (Naomi), Li, Q. (Qiang), Mark, P. B. (Patrick B.), Würtz, P. (Peter), Ala-Korpela, M. (Mika), Marre, M. (Michel), Poulter, N. (Neil), Hamet, P. (Pavel), Chalmers, J. (John), Woodward, M. (Mark), Sattar, N. (Naveed), Welsh, P. (Paul), Rankin, N. (Naomi), Li, Q. (Qiang), Mark, P. B. (Patrick B.), Würtz, P. (Peter), Ala-Korpela, M. (Mika), Marre, M. (Michel), Poulter, N. (Neil), Hamet, P. (Pavel), Chalmers, J. (John), Woodward, M. (Mark), and Sattar, N. (Naveed)
- Abstract
Aims/hypotheses We aimed to quantify the association of individual circulating amino acids with macrovascular disease, microvascular disease and all-cause mortality in individuals with type 2 diabetes. Methods: We performed a case-cohort study (N = 3587), including 655 macrovascular events, 342 microvascular events (new or worsening nephropathy or retinopathy) and 632 all-cause mortality events during follow-up, in a secondary analysis of the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study. For this study, phenylalanine, isoleucine, glutamine, leucine, alanine, tyrosine, histidine and valine were measured in stored plasma samples by proton NMR metabolomics. Hazard ratios were modelled per SD increase in each amino acid. Results: In models investigating associations and potential mechanisms, after adjusting for age, sex and randomised treatment, phenylalanine was positively, and histidine inversely, associated with macrovascular disease risk. These associations were attenuated to the null on further adjustment for extended classical risk factors (including eGFR and urinary albumin/creatinine ratio). After adjustment for extended classical risk factors, higher tyrosine and alanine levels were associated with decreased risk of microvascular disease (HR 0.78; 95% CI 0.67, 0.91 and HR 0.86; 95% CI 0.76, 0.98, respectively). Higher leucine (HR 0.79; 95% CI 0.69, 0.90), histidine (HR 0.89; 95% CI 0.81, 0.99) and valine (HR 0.79; 95% CI 0.70, 0.88) levels were associated with lower risk of mortality. Investigating the predictive ability of amino acids, addition of all amino acids to a risk score modestly improved classification of participants for macrovascular (continuous net reclassification index [NRI] +35.5%, p < 0.001) and microvascular events (continuous NRI +14.4%, p = 0.012). Conclusions/interpretation: We report distinct associations between circulating amino acids and risk of differ
- Published
- 2018
44. Defining success factors to describe coordinated care in cancer
- Author
-
Shaw, T, York, S, White, K, McGregor, D, Rankin, N, Hawkey, A, Aranda, S, Rushton, S, Currow, D, Shaw, T, York, S, White, K, McGregor, D, Rankin, N, Hawkey, A, Aranda, S, Rushton, S, and Currow, D
- Abstract
© Society of Behavioral Medicine 2018. All rights reserved. Providing coordinated care remains a challenge for cancer services globally. There is a lack of consensus in the literature about what constitutes successful coordinated care. This study aimed to define and prioritize a set of consensus-driven success factors that can lead to coordinated care. A mixed-methods approach was used that included literature review, a broad call for submissions from relevant stakeholders, and a priority-setting process based on a modified nominal group technique. Thirty articles that related to success factors in coordinated care were identified in the literature. Twenty submissions were received from a broad range of stakeholders. From these sources, a set of 20 success factors was derived. Seventy stakeholders attended a series of workshops across New South Wales, Australia, to review and prioritize these 20 success factors against significance and measurability. Clear consensus was reached on prioritizing two success factors linked to improving coordinated care from first presentation to diagnosis and ensuring that patients are routinely screened for physical and supportive care needs. Other highly ranked factors included the need for a comprehensive care plan and the identification of patients at higher risk for disjointed care. This study defines and prioritizes a set of success factors related to coordinated care in cancer. These success factors will be used to guide the development of interventions that target improving coordinated care as well as supporting the development of new funding models based on performance indicators derived from these factors.
- Published
- 2018
45. Consensus minimum data set for lung cancer multidisciplinary teams: Results of a Delphi process
- Author
-
Stone, E, Rankin, N, Phillips, J, Fong, K, Currow, DC, Miller, A, Largey, G, Zielinski, R, Flynn, P, Shaw, T, Stone, E, Rankin, N, Phillips, J, Fong, K, Currow, DC, Miller, A, Largey, G, Zielinski, R, Flynn, P, and Shaw, T
- Abstract
© 2018 Asian Pacific Society of Respirology Background and objective: While multidisciplinary team (MDT) care in lung cancer is widely practiced, there are few guidelines for MDT on best data collection strategies. MDT meetings need ready access to information for the provision of optimal treatment recommendations (the primary purpose of the meeting), audit of team performance and benchmarking. This study aimed to develop a practical data set designed for these goals through a recognized consensus process with health professionals who participate in formal MDT settings. Methods: A modified Delphi process with three iterations (two surveys and one consensus conference) was carried out involving over 100 Australian lung cancer MDT health professionals. Results: In total, 122 lung cancer MDT health professionals responded to the Round 1 survey from over 350 invitees. Of the 122, 98 were available for invitation to Round 2. Of 98, 52 (53%) invitees responded to the Round 2 survey. After two rounds, 51 data elements across 8 domains (patient demographics, risk factors, biopsy data, staging, timeliness, treatment, follow-up and patient selection) achieved consensus, defined as 80% agreement. For Round 3, 33 MDT lead clinicians were invited to participate in a consensus conference. Of 33, 14 (42%) invitees distilled the 47 data elements into 23 elements across 8 domains to address the study objectives. Conclusion: A practical data set for lung cancer MDT to use for optimal treatment recommendations and to evaluate team performance was developed through recognized consensus methodology. Access to streamlined, relevant and feasible data collection strategies may improve MDT decision-making, audit of team performance and facilitate benchmarking.
- Published
- 2018
46. Development and pilot testing of a Decision Aid (DA) for women with early-stage breast cancer considering contralateral prophylactic mastectomy
- Author
-
Ager, B, Jansen, J, Porter, D, Phillips, KA, Glassey, R, Rankin, N, Musiello, T, Boyle, F, Zdenkowski, N, Skandarajah, A, Saunders, C, Sundaresan, P, De Abreu Lourenco, R, Butow, P, Ager, B, Jansen, J, Porter, D, Phillips, KA, Glassey, R, Rankin, N, Musiello, T, Boyle, F, Zdenkowski, N, Skandarajah, A, Saunders, C, Sundaresan, P, De Abreu Lourenco, R, and Butow, P
- Abstract
© 2018 Elsevier Ltd Objective: Describe the development, acceptability and feasibility of a Decision Aid (DA) for women with early-stage breast cancer (BC) at average contralateral breast cancer (CBC) risk considering contralateral prophylactic mastectomy (CPM). Methods: The DA was developed using the International Patient Decision Aid Standards (IPDAS) and the Ottawa Decision Support Framework. It provides evidence-based information about CPM in a booklet format combining text, graphs and images of surgical options. Twenty-three women with a history of early-stage breast cancer were interviewed in person or over the phone using a ‘think aloud approach’. Framework analysis was used to code and analyse data. Results: Twenty-three women participated in the study. Mean age of participants was 58.6 years and time since diagnosis ranged from 14 months to 21 years. Five women had CPM and eighteen had not. Women strongly endorsed the DA. Many felt validated by a section on appearance and found information on average risk of recurrence and metastases helpful, however, noted the importance of discussing personal risk with their surgeon. Many requested more information on surgery details (time taken, recovery) and costs of the different options. Conclusion: The DA was acceptable to women, including the format, content and proposed implementation strategies. Practical and financial issues are important to women in considering treatment options. Practice implications: Women appreciate information about CPM at diagnosis and emphasised the importance of discussing potential downsides of the procedure in addition to benefits. The DA was considered acceptable to facilitate such discussions.
- Published
- 2018
47. Does presentation at multidisciplinary team meetings improve lung cancer survival? Findings from a consecutive cohort study
- Author
-
Stone, E, Rankin, N, Kerr, S, Fong, K, Currow, DC, Phillips, J, Connon, T, Zhang, L, Shaw, T, Stone, E, Rankin, N, Kerr, S, Fong, K, Currow, DC, Phillips, J, Connon, T, Zhang, L, and Shaw, T
- Abstract
© 2018 Elsevier B.V. Background: Multidisciplinary team (MDT) presentation in lung cancer has the potential to improve longterm outcomes, although this varies between studies. This study aims to evaluate outcomes including survival, according to MDT presentation and to explore the utility of data obtained from local clinical sources. Patients and methods: Prospective cases of lung cancer recorded in our institution's cancer registry were analyzed according to MDT presentation for patient and tumour characteristics, adjusted survival and referral to palliative care. Results: 1197 cases were included, 295 (24.6%) with MDT presentation and 902 (75.4%) without. 60% of patients were male with median (IQR) age at diagnosis of 70 years (62–78). Histopathology distribution (non-small cell lung cancer and small-cell lung cancer) was similar between the two groups. Compared with the non-MDT group, the MDT group had (1) ECOG score recorded more often (71.9% vs. 47.6%), (2) higher proportion of ECOG 0 cases (31.2% vs. 11.9%) and ECOG 1 cases (28.8% vs. 20.3%), (3) higher proportion of early stage disease (stage I - 23.1% vs. 9.7% stage II - 10.2% vs. 4.8%, stage IIIA - 14.6% vs 6.3%) and (4) lower proportion of metastatic disease (stage IV - 39.3% vs. 56.1%). Referral to palliative care was incompletely recorded in both groups (MDT: n = 116/295, 39.3%; non-MDT: n = 430, 47.7%) but did not differ significantly for stage IV cases. Survival analyzed by stage was greater in the MDT group at 1, 2 and 5 years for all stages except stage IIIB at 1 year post-diagnosis. Adjusted survival analysis for the entire cohort showed improved survival at 5 years for the MDT group (HR 0.7 (0.58-0.85), p < 0.001). Conclusion: MDT presentation is associated with improved adjusted survival for lung cancer in this single institutional cohort in an analysis of local clinical cancer registry data.
- Published
- 2018
48. MetaNetter 2: A Cytoscape plugin for ab initio network analysis and metabolite feature classification
- Author
-
Borutzki, Y., Rankin, N., Daly, R., Jourdan, Fabien, and Burgess, Karl E.V.
- Subjects
ab-initio network ,mass spectrometry ,MetaNetter ,metabolomics - Abstract
Metabolomics frequently relies on the use of high resolution mass spectrometry data. Classification and filtering of this data remain a challenging task due to the plethora of complex mass spectral artefacts, chemical noise, adducts and fragmentation that occur during ionisation and analysis. Additionally, the relationships between detected compounds can provide a wealth of information about the nature of the samples and the biochemistry that gave rise to them. We present a biochemical networking tool: MetaNetter 2 that is based on the original MetaNetter, a Cytoscape plugin that creates ab initio networks. The new version supports two major improvements: the generation of adduct networks and the creation of tables that map adduct or transformation patterns across multiple samples, providing a readout of compound relationships. We have applied this tool to the analysis of adduct patterns in the same sample separated under two different chromatographies, allowing inferences to be made about the effect of different buffer conditions on adduct detection, and the application of the chemical transformation analysis to both a single fragmentation analysis and an all-ions fragmentation dataset. Finally, we present an analysis of a dataset derived from anaerobic and aerobic growth of the organism Staphylococcus aureus demonstrating the utility of the tool for biological analysis.
- Published
- 2017
49. AMDAT Lung, An Ideal Lung Cancer MDT Dataset
- Author
-
Stone, E, Rankin, N, Phillips, J, Fong, K, Miller, A, Largey, G, Zielinski, R, Flynn, P, Currow, D, and Shaw, T
- Subjects
Oncology & Carcinogenesis - Published
- 2017
50. MetaNetter 2: A Cytoscape plugin for ab initio network analysis and metabolite feature classification
- Author
-
Burgess, K.E.V., Borutzki, Y., Rankin, N., Daly, R., Jourdan, S., University of Glasgow, Institute of Infection, Immunity and Inflammation, Institute of Cardiovascular and Medical Sciences, Métabolisme et Xénobiotiques (ToxAlim-MeX), ToxAlim (ToxAlim), Institut National de la Recherche Agronomique (INRA)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Ecole d'Ingénieurs de Purpan (INPT - EI Purpan), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Recherche Agronomique (INRA)-Université Toulouse III - Paul Sabatier (UT3), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées
- Subjects
Staphylococcus aureus ,Databases, Factual ,Mass spectrometry ,MetaNetter ,[SDV]Life Sciences [q-bio] ,Computational Biology ,Ab-initio network ,metabolomics ,ab-initio network ,Aerobiosis ,Article ,metaNetter ,Metabolomics ,Anaerobiosis ,Software ,mass spectrometry - Abstract
Highlights • An update to the ab-initio network construction tool MetaNetter has been produced. • The tool creates networks of masses from high resolution mass spectrometry data. • The new plugin provides both chemical transformation and adduct mapping. • Tables mapping adduct and transform counts across samples can be generated. • Retention time windows are supported for both adduct and transform network generation., Metabolomics frequently relies on the use of high resolution mass spectrometry data. Classification and filtering of this data remain a challenging task due to the plethora of complex mass spectral artefacts, chemical noise, adducts and fragmentation that occur during ionisation and analysis. Additionally, the relationships between detected compounds can provide a wealth of information about the nature of the samples and the biochemistry that gave rise to them. We present a biochemical networking tool: MetaNetter 2 that is based on the original MetaNetter, a Cytoscape plugin that creates ab initio networks. The new version supports two major improvements: the generation of adduct networks and the creation of tables that map adduct or transformation patterns across multiple samples, providing a readout of compound relationships. We have applied this tool to the analysis of adduct patterns in the same sample separated under two different chromatographies, allowing inferences to be made about the effect of different buffer conditions on adduct detection, and the application of the chemical transformation analysis to both a single fragmentation analysis and an all-ions fragmentation dataset. Finally, we present an analysis of a dataset derived from anaerobic and aerobic growth of the organism Staphylococcus aureus demonstrating the utility of the tool for biological analysis.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.